Researchers Identify Molecular Target for Brain Cancer, Develop Immunotherapy Approach to Attack It
An international team of researchers has genetically engineered cancer-killing immune cells that can hunt brain tumors displaying a new molecular target that is highly prevalent on brain cancer cells. Based on the findings from their early, preclinical studies, the researchers believe their approach holds promise for a new immunotherapy treatment for glioblastoma, which is the most lethal primary brain tumor.
Researchers from the University of North Carolina Lineberger Comprehensive Cancer Center, in collaboration with the Fondazione Istituto di Ricerca e Cura a Carattere Scientifico in Milan, Italy, report they modified immune cells to hunt brain tumors displaying a new molecular target called CSPG4, which they determined is highly prevalent on brain cancer cells. Their preclinical studies of immune cells engineered to recognize CSPG4 showed promise for controlling tumor growth in mouse and cell models for glioblastoma.
Click here to read more.
NeuroSafe 2019 Symposium
Aug. 8-9, 2019; Minneapolis
SNSA Congress 2019
Aug. 8-11, 2019; Cape Town, South Africa
2019 Managing Coding and Reimbursement Challenges
Aug. 22-24, 2019; Rosemont, Ill.
2019 From Cranial to Spine: An Overview of Neurosurgical Topics for the Advanced Practice Provider
Aug. 28-31, 2019; Orlando, Fla.
Sept. 8-11, 2019; Leuven, Belgium